



## Ind-Swift LABORATORIES LIMITED

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, 5061850, 5061853  
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com  
CIN No. L24232CH1995PLC015553



Ref: ISLL:CH:2025

Date: 4<sup>th</sup> July, 2025

**The President  
Corporate Relationship Department  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai 400 001**

**The Vice President,  
Listing Compliance Department,  
National Stock Exchange of India Limited,  
Exchange Plaza, 5<sup>th</sup> Floor  
Plot No. C/2, G-Block,  
Bandra Kurla Complex, Bandra (E),  
Mumbai 400 051**

**BSE Scrip Code: 532305**

**NSE Symbol: INDSWFTLAB**

**SUB: Disclosure under Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015**

Dear Sir/Ma'am,

We have received Form C under Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 from M/s Essix Biosciences Limited, regarding acquisition of 11,00,000 equity shares upon conversion of equivalent numbers of warrants into equity.

We request you to treat this intimation as compliance with the aforesaid regulations and take the same on record.

For **IND-SWIFT LABORATORIES LTD.**

**PARDEEP VERMA  
VP-CORPORATE AFFAIRS &  
COMPANY SECRETARY**

Encl: a/a



# ESSIX BIOSCIENCES LIMITED

Regt. Office: SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh-160101 (India)  
CIN: U74999CH1993PLC033428  
Ph. +91-172-2730503, 2730920, Fax: +91-172-2730504, 2736294

Date: July 04, 2025

To,  
Company Secretary & Compliance Officer  
Ind- Swift Laboratories Limited  
SCO:850, Shivalik Enclave, NAC,  
Manimajra, Chandigarh -160101, India

**Subject: Submission of disclosure under Regulation 7(2)(a) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015**

Dear Sir/Madam,


With reference to the above-captioned subject, please note that I, Himanshu Jain, on behalf of Essix Biosciences Limited, Promoter of Ind-Swift Laboratories Limited ("the Company") have acquired 11,00,000 Equity Shares pursuant to the conversion of fully convertible warrants of the Company having Face Value of Rs. 10/- each representing 1.64% of the post allotment paid-up equity share capital of the Company on July 02, 2025, on a preferential allotment basis.

In reference to the above, kindly find enclosed herewith the disclosure required under Regulation 7(2)(a) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

Kindly take the above information on your records.

For ESSIX BIOSCIENCES LIMITED

  
HIMANSHU JAIN  
DIRECTOR  
DIN: 00014533




**FORM C**  
**SEBI (PROHIBITION OF INSIDER TRADING) REGULATIONS, 2015**  
**[REGULATION 7 (2) READ WITH REGULATION 6(2) – CONTINUAL DISCLOSURE]**

Name of the Company: IND- SWIFT LABORATORIES LIMITED  
 ISIN of the Company: INE915B01019

Details of change in holding of Securities of Promoter, Member of the Promoter Group, Designated Person or Director of a listed company and immediate relatives of such persons and other such persons as mentioned in Regulation 6(2)

Name, PAN, CIN/DIN, & address with contact nos.	Category of Person (Promoter/m member of the promoter group/designated person/Director s/immediate relative to/others etc.)	Securities held prior to acquisition/disposal		Securities acquired/Disposed				Securities held post acquisition/disposal		Date of allotment advice/ acquisition of shares/ sale of shares specify		Date of Intimation to company	Mode of acquisition / disposal (on market/public/ rights/ preferential offer / off market/Inter-se transfer, ESOPs etc.)	Exchange on which the trade was executed
		Type of securities (For e.g. – Shares, Warrants, Convertible Debentures, Rights entitlements etc.)	No. and % of shareholding	Type of securities (For e.g. – Shares, Warrants, Convertible Debentures, Rights entitlement, etc.)	No.	#Value (in Rs.)	Transaction Type (Buy/ Sale/ Pledge / Revoke/ Invoke)	Type of securities (For e.g. – Shares, Warrants, Convertible Debentures, Rights entitlement, etc.)	No. and % of Shareholding	From	To			
Name: Essix Biosciences Limited PAN: <span style="background-color: black; color: black;">XXXXXXXXXX</span> Registered Office Address: SCO 850, Shivalik Enclave, Chandigarh-160101, India Contact No.: 0172-2730503	Promoter	Equity Shares	2,23,27,507 36.83%*	Equity Shares pursuant to the conversion of Fully Convertible Warrants	11,00,000 1.64%**	13,31,00,000 #	Buy	Equity Shares	2,34,27,507 34.86%**	July 02, 2025	July 02, 2025	04-07-2025	Allotment of Equity Shares pursuant to the conversion of Fully Convertible Warrants, on Preferential basis	NA



(\*) These percentages have been calculated on the basis of the pre-issue share capital of the Company i.e. Rs. 60,61,88,600/- (Sixty Crore Sixty-One Lakh Eighty-Eight Thousand Six Hundred Only) divided into 6,06,18,860 (Six Crore Six Lakh Eighteen Thousand Eight Hundred Sixty) Equity Shares of face value Rs. 10/- each.

(\*\*) These percentages have been calculated on the basis of the post-issue share capital of the Company i.e. Rs. 67,20,17,360/- (Sixty-Seven Crore Twenty Lakh Seventeen Thousand Three Hundred Sixty Only) divided into 6,72,01,736 (Six Crore Seventy-Two Lakh One Thousand Seven Hundred Thirty-Six) Equity Shares of face value of Rs. 10/- each.

(#) This value has been calculated on the basis of the issue price at which allotment was made by the Company i.e. Rs. 121/- each.

**Details of trading in derivatives of the company by Promoter, Employee or Director of a listed company and other such persons as mentioned in Regulation 6(2).**

Trading in derivatives (Specify type of contract, Futures or Options etc.)					Exchange on which the trade was executed	
Type of contract	Contract specifications	Buy		Sell		
		Notional Value	Number of units (contracts * lot size)	Notional Value	Number of units (contracts * lot size)	
N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.

Note: In case of Options, notional value shall be calculated based on Premium plus strike price of options.

For Essix Biosciences Limited



HIMANSHU JAIN

Designation: Director & Promoter



Date: 04-07-2025

Place: Chandigarh